Fifteen years ago I had the dubious honor of being employed (as one of two lowly programmers, not a manager) by one of the first internet startups whose only goal was to have an IPO - Initial Public Offering of stock. The company was called 'Unimation'. The 'founders' had no interest in creating a revenue-generating product or service. The whole point was to sell their stock to fools with more money than sense.
The enterprise collapsed when my manager blew the whistle. Much of the original investment went up 'the founders' noses, and they left town in the middle of the night - literally.
All this talk about Hemispherx stock price reminds me of that sorry episode. Unless drug approval spurs the sale of more stock (thus diluting the value of current owners' stock), the stock price is mostly irrelevant to the company's operations. In other words, higher stock price doesn't give the company more cash to spend on research or production. A higher stock price would give current shareholders a chance to bail at a profit, but it won't help us.
Like
Firestormm wrote, as long as the stock price changes, *someone* will benefit, but it won't be patients.